Unlocking the Potential of Ribosomal Protein L17 Pseudogene 34 as a Drug Target or Biomarker

Target Name: RPL17P34

NCBI ID: G643863

RPL17P34

Other Name(s): ribosomal protein L17 pseudogene 34 | RPL17_10_1081 | Ribosomal protein L17 pseudogene 34

Unlocking the Potential of Ribosomal Protein L17 Pseudogene 34 as a Drug Target or Biomarker

Ribosomal protein (RP) L17 (also known as RP L17) is a protein that plays a crucial role in the process of translation of mRNA into proteins. It is composed of a cytoplasmic domain and a transmembrane region that contains a unique framework of 26 amino acids. RPL17 is expressed in most eukaryotic cells and is highly conserved across different species. It has been implicated in various cellular processes, including cell signaling, DNA replication, and protein folding.

Recent studies have identified potential drug targets and biomarkers for RPL17. In this article, we will explore the biology and functions of RPL17, with a focus on its potential as a drug target and biomarker.

The biology of RPL17

RPL17 is a 26- amino acid protein that is expressed in most eukaryotic cells. It is highly conserved across different species, with only minor differences in the amino acid sequence. RPL17 is primarily localized to the cytoplasm and has been implicated in various cellular processes, including cell signaling, DNA replication, and protein folding.

One of the unique features of RPL17 is its framework, which consists of a series of 26 amino acids that are arranged in a specific order. This order is highly conserved across different species, suggesting that it plays a crucial role in the stability and proper functioning of the RP complex.

Expression and localization of RPL17

RPL17 is highly expressed in most eukaryotic cells and is primarily localized to the cytoplasm. It is not well-known to date, and its function and localization to specific cellular processes are not well understood. However, studies using techniques such as immunofluorescence and biochemical assays have shown that RPL17 is expressed in various cellular organelles, including the endoplasmic reticulum, mitochondria, and endoplasmic reticulum-associated vesicles.

Function of RPL17

RPL17 has been implicated in various cellular processes, including cell signaling, DNA replication, and protein folding. One of the well-documented functions of RPL17 is its role in the process of mRNA translation. RPL17 is a key component of the RP complex, which is responsible for translating mRNA into proteins.

In addition to its role in mRNA translation, RPL17 has also been shown to play a role in regulating protein folding. Studies have shown that RPL17 can interact with various protein partners, including the protein TRF2, to prevent protein misfolding and promote protein folding into functional forms.

Potential drug targets and biomarkers for RPL17

Several studies have identified potential drug targets and biomarkers for RPL17. One of the most promising targets is the protein ID4, which is a known protein interactor with RPL17. ID4 has been shown to play a role in regulating the stability of RPL17 and may be a potential drug target for RPL17-related diseases.

Another potential drug target for RPL17 is the protein K633, which is a known protein interactor with RPL17 and has been shown to play a role in regulating protein folding. K633 may be a potential biomarker for RPL17-related diseases.

Conclusion

RPL17 is a protein that has been shown to play a crucial role in various cellular processes. Its unique framework and conservation across different species suggest that it may be a potential drug target or biomarker. Further studies are needed to fully understand the functions of RPL17 and its potential as a drug target or biomarker.

Protein Name: Ribosomal Protein L17 Pseudogene 34

The "RPL17P34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL17P34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets